Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPRIA: Atezolizumab and Sacituzumab Govitecan in Residual TNBC
NCT04434040Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Jul 2020; status: recruiting.
02
Drugs
atezolizumabsacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04434040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04434040.